A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Active, not recruiting
Deciphera Pharmaceuticals LLC
Phase 1
2015-10-01
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to
evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and
preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with
advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an
expansion phase. All active patients (from both dose-escalation and expansion phases) will
then transition into an extension phase.
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
Active, not recruiting
Deciphera Pharmaceuticals LLC
Phase 3
2018-02-27
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter
study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have
received treatment with prior anticancer therapies. Prior anticancer therapies must include
imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were
randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Active, not recruiting
Deciphera Pharmaceuticals LLC
Phase 3
2019-02-11
This is a 2-arm, randomized, open-label, international, multicenter study comparing the
efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to
first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized
in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or
sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.